Floatz logo

Optimized Neoantigen Synthetic Long Peptide Vaccine

Infiltrating Bladder Urothelial Carcinoma

Washington University School of MedicinevaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the Infiltrating Bladder Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2/3B
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2/3B
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2/3B
CIS-DIAMMINEDICHLOROPLATINUM II
Vasgene Therapeutics, Inc
Phase 2/3B
Relatlimab
National Cancer Institute (NCI)
Phase 2/3B

View all 15 →

Same molecule, other indications

Optimized Neoantigen Synthetic Long Peptide Vaccine is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
42 / 100
View asset →
pancreatic neoplasmDormant
C
Indicative ·
39 / 100
View asset →
gastroesophageal adenocarcinomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →